Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

41.10
+1.854.71%
Post-market: 41.210.1100+0.27%19:59 EDT
Volume:14.82M
Turnover:610.54M
Market Cap:47.88B
PE:68.50
High:42.02
Open:40.22
Low:40.12
Close:39.25
52wk High:42.02
52wk Low:18.83
Shares:1.17B
Float Shares:1.09B
Volume Ratio:3.10
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:6.18
PE(LYR):33.97

Loading ...

Teva Pharmaceuticals is Maintained at Buy by UBS

Dow Jones
·
Sep 05

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

TIPRANKS
·
Sep 03

Teva Upgraded to Buy on Strengthening Autoimmune Pipeline and Validating Celiac Disease Data

TIPRANKS
·
Sep 03

US-Listed Shares of Teva Pharmaceutical up 3.5% Premarket After Co's Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

THOMSON REUTERS
·
Sep 02

Teva's Stock Jumps over 3% as Immune Disorder Drug Meets Main Goal in Mid-Stage Trial

Reuters
·
Sep 02

Movement Alert|Teva Pharmaceutical Rises 5.11% in Pre-Market Trading, Positive Phase 2a Data for Anti-IL-15 Drug TEV-408 in Celiac Disease

Market Focus
·
Sep 02

Teva Pharmaceutical Reports Positive Topline Data for Anti-IL-15 Drug in Celiac Disease

MT Newswires Live
·
Sep 02

Teva: Tev '408 was Well-Tolerated with no Safety Signals Observed to Date

THOMSON REUTERS
·
Sep 02

Teva - Tev ‘408 Demonstrates Statistically Significant Prevention of Gluten-Induced Damage in Phase 2a Study

THOMSON REUTERS
·
Sep 02

Teva - Phase 2a Study Meets Primary Endpoint with Significant Prevention of Gluten-Induced Damage

THOMSON REUTERS
·
Sep 02

Is Teva Pharmaceutical Industries (TEVA) Undervalued On Its FDA Filing News Or Already Fully Valued?

Simply Wall St.
·
Sep 02

Introducing Trailpeak: Teva’s First High Performance Daily Trail Running Shoe Co-Created with the Brand’s Bureau of Adventure Athletes

THOMSON REUTERS
·
Sep 01

White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies

MT Newswires Live
·
Sep 01

Dow Jones Top Company Headlines at 9 PM ET: Anthropic Signs $35 Billion Cloud Deal Backed by Nvidia | UPS ...

Dow Jones
·
Sep 01

Stocks to Watch: Sono Group, Teva Pharmaceuticals, Pyxis Tankers, Metallus

Dow Jones
·
Sep 01

Teva to lower cost of select medicines for American patients covered by Medicaid

TIPRANKS
·
Sep 01

Etsy, ConocoPhillips, Intuit, Teva, Rithm: Insider Cashouts

TIPRANKS
·
Aug 29

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

GlobeNewswire
·
Aug 28

Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Aug 27